Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025Blood

Short-term follow-up results of ultra-low-dose radiotherapy for indolent B-cell lymphoma

View Full Paper
Ask AI
Bookmark
Share

Authors

MLMin LiHWHao Wang

Discussion

Loading...

Member takes

Overview

Retrospective analysis shows 36% complete response in indolent B-cell lymphoma with low-dose radiotherapy, indicating its efficacy and safety.

Key Points

  • To evaluate the short-term efficacy and safety of ultra-low-dose radiotherapy in patients with indolent B-cell lymphoma.
  • Retrospective analysis of 14 patients treated with 4 Gy ultra-low-dose radiotherapy.
  • Patients received a total of 4 Gy in 2 fractions of 2 Gy each.
  • Primary endpoints included response rate, locoregional failure-free survival, and progression-free survival.
  • Complete response observed in 35.7% of cases (n = 5).
  • Partial response seen in 42.9% (n = 6).
  • One-year locoregional failure-free survival rate was 91.7%.
  • No grade 3 or higher treatment-related toxicities were recorded.

Cite This Study

Li et al. (2025) studied this question.

synapsesocial.com/papers/69362f574fa91c937236da38https://doi.org/10.1182/blood-2025-7113
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Radiotherapy for indolent primary cutaneous B-cell lymphoma: an international multicenter ILROG analysis2026 · 1 citations
  2. 2Ultra‐low dose radiation therapy for primary cutaneous indolent B‐cell lymphomas2024 · 4 citations
  3. 3Definitive radiotherapy for early-stage follicular lymphoma: A retrospective study over two decades at a single institution2026
  4. 4Single-agent rituximab and ultra-low-dose adaptive radiotherapy for the treatment of indolent B-cell non-Hodgkin lymphomas2025 · 1 citations
  5. 5Clinical Outcomes and Safety of Ultra-Low-Dose Radiotherapy for Ocular Adnexal Lymphoma: A Systematic Review2025